Press-release for stocks in the health technology sector for mrk

Prices are updated after-hours

sector : Health technology symbols : Mrk

save search

Health Canada Approves KEYTRUDA as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma
Published: 2024-04-19 (Crawled : 13:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M

Health Technology

| 0.33% | O: 0.22% H: 0.37% C: 0.1%
health treatment for canada advanced keytruda

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M

Health Technology

| -3.63% | O: 0.24% H: 0.08% C: -2.42%
mk-1084 keytruda lung merck cancer cell treatment trial

REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Published: 2024-04-03 (Crawled : 13:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M

Health Technology

| -3.51% | O: 0.13% H: 0.0% C: 0.0%
cancer trial initiated

Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
Published: 2024-04-01 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M

Health Technology

| -4.7% | O: -0.23% H: 0.19% C: -0.52%
sales conference merck

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Adults
Published: 2024-03-28 (Crawled : 11:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M

Health Technology

| -4.53% | O: 0.18% H: 0.0% C: 0.0%
keytruda lung cancer cell risk plus

Merck Foundation Strengthens Its Commitment to Expanding Access to Care in Asia-Pacific Region
Published: 2024-03-26 (Crawled : 00:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M

Health Technology

| 0.38% | O: 0.38% H: 0.24% C: -0.21%
merck care foundation

FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
Published: 2024-03-26 (Crawled : 23:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M

Health Technology

| 0.38% | O: 0.38% H: 0.24% C: -0.21%
fda group treatment hypertension

Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
Published: 2024-03-21 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M

Health Technology

| 1.56% | O: -0.13% H: 0.4% C: -0.06%
ylynk-006 keytruda lung merck update cancer cell trial plus

Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
Published: 2024-03-19 (Crawled : 13:30) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M

Health Technology

| 3.57% | O: 0.0% H: 0.68% C: 0.63%
pneumococcal vaccine merck positive

FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform
Published: 2024-03-15 (Crawled : 21:00) - prnewswire.com
MRK | News | $125.78 0.44% 0.0% 8.4M

Health Technology

| Email alert Add to watchlist
platform

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Published: 2024-03-15 (Crawled : 11:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M

Health Technology

| 4.37% | O: -0.56% H: 1.75% C: 1.4%
keytruda cancer alone advanced plus

Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
Published: 2024-03-13 (Crawled : 11:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M

Health Technology

| 2.54% | O: 0.41% H: 0.04% C: -0.81%
gardasil vaccine merck trials

Merck Completes Acquisition of Harpoon Therapeutics, Inc.
Published: 2024-03-11 (Crawled : 16:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M

Health Technology

| 1.85% | O: 0.93% H: 0.0% C: -1.51%
merck acquisition

Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-27 (Crawled : 13:00) - biospace.com/
TVTX | $5.73 -1.21% -1.22% 950K

Health Technology

| -28.68% | O: 2.37% H: 1.46% C: 1.22%
MRK | News | $125.78 0.44% 0.0% 8.4M

Health Technology

| -2.38% | O: -0.45% H: 0.7% C: 0.6%
HTGC F | $18.46 1.15% 0.38% 660K

Finance

| -1.65% | O: -2.77% H: 0.47% C: -0.27%
VKTX | $63.38 -2.0% -2.04% 3M

Health Technology

| 64.81% | O: 81.31% H: 29.0% C: 21.9%
VRNA | $15.82 -1.74% -1.83% 640K

Health Technology

| -10.83% | O: 2.1% H: 2.83% C: -0.5%
LGND | $72.59 0.1% 0.1% 140K

Health Technology

| -2.62% | O: 14.46% H: 11.02% C: 4.72%
ALDX | $3.865 -2.89% -2.98% 430K

Health Technology

| 5.46% | O: 1.91% H: 2.68% C: 1.07%
year financial results

MERCK CANADA ANNOUNCES COLLABORATION WITH VECTOR INSTITUTE TO FURTHER ADVANCE ITS ARTIFICIAL INTELLIGENCE CAPABILITIES AND DRIVE INNOVATION IN HEALTHCARE
Published: 2024-02-08 (Crawled : 13:30) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M

Health Technology

| -1.33% | O: -0.12% H: 0.13% C: -0.56%
institute intelligence merck innovation collaboration canada

Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results
Published: 2024-02-01 (Crawled : 23:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -8.22% | O: -4.37% H: 0.0% C: 0.0%
MRK | News | $125.78 0.44% 0.0% 8.4M

Health Technology

| 4.14% | O: 2.38% H: 2.25% C: 2.21%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -9.48% | O: -5.26% H: 0.0% C: 0.0%
MRNA S | $101.44 -0.55% -0.55% 2.6M

Health Technology

| 0.36% | O: -0.15% H: 0.1% C: -1.86%
HARP | $23.01 0.07% 6.6M

Health Technology

| 2.96% | O: 0.0% H: 0.0% C: 0.0%
merck financial results

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery
Published: 2024-01-26 (Crawled : 23:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M

Health Technology

| 4.7% | O: 0.32% H: 0.42% C: 0.26%
keytruda advanced therapy

Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1
Published: 2024-01-19 (Crawled : 14:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M

Health Technology

| 6.11% | O: -0.28% H: 0.68% C: 0.58%
sales conference merck

Merck Animal Health's Fourth Veterinary Wellbeing Study Indicates Progress in Addressing Mental Health Challenges Among Veterinary Teams
Published: 2024-01-15 (Crawled : 13:30) - prnewswire.com
MRK | News | $125.78 0.44% 0.0% 8.4M

Health Technology

| Email alert Add to watchlist
veterinary health animal merck study

Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
Published: 2024-01-08 (Crawled : 13:30) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800

Health Technology